September 13 2023, 3-6:30 pm (CEST), 9-12 am (EDT) 6-9:30 am (PDT) – Virtual webinar
Purpose
This webinar is to discuss issues related to global demand for vaccine adjuvants and the associated research and development, as well as facilitating global access to novel adjuvants and formulation technologies for vaccine developers.
Audience
Scientists, product developers, regulators, policy makers, implementers and funders interested in the role of vaccines adjuvants.
Topics
- Global Demand for Vaccine Adjuvants:
- Needs for a global market;
- Adjuvants for pandemic preparedness;
- Empowering public health: strengthening capacity for global supply, accessibility and affordability for adjuvants and formulations.
- Selection of adjuvant and formulation for vaccine R&D, rational or empirical:
- Molecular mechanism of adjuvants and how to best present to immune system;
- Formulation impact on vaccine performance;
- Adjuvant performance in target populations - RV460 HIV vaccine trial in Kenya;
- Regulatory considerations for adjuvants for new and improved vaccines.
- Access to adjuvants “speed dating” for vaccine developers:
- Novel synthetic Th1 and Th17 inducing adjuvants;
- Advax-CpG adjuvant;
- Alhydroxiquim-II;
- The CAF adjuvant platform: a versatile adjuvant/delivery platform for proteins & peptides;
- ALF adjuvant;
- Intranasal vaccine adjuvant for prevention of respiratory and sexually-transmitted infections;
- dmLT/LTA1 adjuvant;
- BECC family of adjuvants;
- VFI adjuvant portfolio;
- AAHI adjuvant portfolio.
About GVIRF
The Global Vaccine and Immunization Research Forum is the central forum for research related to the Immunization Agenda 2030 (IA2030). GVIRF gathers together leading experts from public health, academia, government, civil society and private sector, and is co-hosted by the U.S. National Institute of Allergy and Infectious Diseases, the Bill & Melinda Gates Foundation and the World Health Organization. Between the global forums, a series of webinars is also organized to address emerging issues of interest.